The global preimplantation genetic testing market is projected to register a CAGR of 10.0% from 2017 to 2022. The rising infertility rate across the world is the key factor driving the growth of the market. Geographically, this market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW).
The global preimplantation genetic testing market is segmented by technology, product & service, procedure type, applications, end user and region. Based on technology, the market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH), and single-nucleotide polymorphism (SNP).
Download PDF Brochure Here : http://www.marketsandmarkets.com/pdfdownload.asp?id=605
The NGS segment is expected to grow at a faster rate owing to the increasing applications of preimplantation genetic testing for different cancer cases. The NGS segment also accounted for the largest share of the global preimplantation genetic testing market in 2016. The large share of this segment can be attributed to the various advantages offered by NGS such as reduced cost, better ability to detect an embryo with differing results (mosaicism), enhanced detection of structural abnormalities such as chromosomes with missing or duplicate segments, and reduction in human errors owing to increased automation.
The global preimplantation genetic testing market, by product & service, is segmented into instruments, reagents & consumables, and software & services. The reagents & consumables segment accounted for the largest share of the global preimplantation testing market in 2016. The large share of this segment can be attributed to the expanding application horizons of specific technologies (such as NGS and aCGH for whole-genome sequencing and FISH in the diagnosis of specific genetic disorders) and rising number of probe-based multiplex genetic analysis.
In 2016, North America accounted for the largest share of the market due to factors such as rising number of IVF procedures (with decreasing fertility rates), significant adoption of genomic techniques, ongoing trend of replacing traditional genomic technologies with advanced and innovative genetic techniques (such as FISH and NGS), and increasing private-public funding to develop and commercialize novel PGS & PGD procedures. However, the Asia-Pacific region is expected to register the highest CAGR during the forecast period. Growth in this market is attributed to the growing number of ART & IVF procedures in the region, continuous decline in average fertility rate, and growing medical tourism across APAC countries.